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Serotype-specific fimbriae of BordeteUla pertussis are considered potential components of new-generation
vaccines against whooping cough. Attempts to characterize fimbriae, and indeed other virulence determinants,
produced by B. pertussis have been frustrated on one hand by low yields from B. pertussis itself and on the other
by an inability to produce native recombinant products in Escherichia coli. In order to try to circumvent this
problem, we have examined the expression of B. pertussis serotype 2 fimbriae in BordeteUa parapertussis and
BordeteUa bronchiseptica from native as well as E. coli expression signals. These studies revealed that the fimbrial
gene product was expressed from the original B. pertussis promoter and Shine-Dalgarno sequence in both B.
parapertussis and B. bronchiseptica. The transcriptional start site of the gene was located 146 nucleotides
upstream of its ATG start codon. A recombinant fimbrial subunit gene containing PLAC and the atpE translation
initiation region of E. coli was also expressed in B. bronchiseptica. In all cases in which gene expression was
detected the gene product was expressed as serotype 2-specific fimbriae as determined by enzyme-linked
immunosorbent assay (ELISA) and immunoelectron microscopic investigation of the bacterial cell surface.
Bordetella pertussis is the causative agent of whooping
cough, a particularly severe disease of young children char-
acterized by repeated bouts of severe paroxysmal coughing.
Until recently this disease was controlled through vaccina-
tion. However, increasing concern about side effects asso-
ciated with immunization with whole-cell preparations of B.
pertussis has led to decreased vaccine acceptability. This in
turn has been accompanied by an increase in the incidence of
whooping cough (22). It is therefore imperative that an
effective, nonreactogenic vaccine of higher acceptability be
developed. Virulence-associated gene products that have
been suggested for incorporation into a purified-component,
acellular vaccine include pertussis toxin, filamentous hem-
agglutinin, serotype-specific fimbriae, adenylate cyclase,
and major outer membrane proteins (21, 22). Expression of
the genes encoding all of these antigens is positively con-
trolled by the virulence regulatory determinant, bvg (6, 11,
29). Purification of such proteins from B. pertussis is ham-
pered by poor bacterial growth rates, low yields, antigenic
variation, and the presence of other reactogenic contami-
nants. To avoid these problems, attempts have been made to
obtain expression of recombinant antigens in Escherichia
coli by using strong transcriptional and translational signals.
The five genes encoding pertussis toxin have been expressed
in E. coli under the control of the lambda PL promoter (3).
The serotype 2 fimbrial subunit gene has also been expressed
from the lambda PL and PR promoters (28). However, in
neither case did the recombinant products assemble to form
products, pertussis holotoxin and serotype 2 fimbriae, re-
spectively, that were immunologically identical to the native
products. On the other hand, pertussis holotoxin is produced
in recombinant Bordetella parapertussis and Bordetella
bronchiseptica and is expressed from its native promoter
(13). Nontoxic mutant pertussis toxin has also been ex-
* Corresponding author.
pressed in B. pertussis (10, 19). In this report, we have
examined the usefulness of E. coli transcriptional and trans-
lational signals for the expression of pertussis components in
faster growing and less fastidious Bordetella spp. and have
constructed broad-host-range expression plasmids contain-
ing the serotype 2 fimbrial subunit gene to determine
whether the fimbrial subunit expressed in B. parapertussis
and B. bronchiseptica is assembled into native serotype 2
fimbriae.
MATERIALS AND METHODS
Bacterial strains, plasmids, and media. The bacterial
strains used in this work and their sources are as follows: B.
pertussis Tohama, 1.2. serotype Fim+ (24); B. pertussis
H36, 1.3 serotype Fim+, and B. parapertussis M/S180 Fim+,
N. Preston; B. bronchiseptica 5376 Fim+, R. Brownlie; B.
pertussis ATCC 9797, 1 serotype Fim-, B. parapertussis
ATCC 15311 Fim+, and B. bronchiseptica ATCC 10580
Fim- and ATCC 19395 Fim-, M. Hofle; E. coli JM109,
endAl recA hsdR supE thi gyr lac-pro F' tra-36proAB lacIqZ
M15 (31); and E. coli CAG629 lon htpR165-TnJO, C. Gross.
The plasmids used in this work were pIL22 (15), pMW3 and
pMW10 (28), pRK600 (5), and pDSK519 (9).
E. coli was grown on Z agar (27), 5-bromo-4-chloro-3-
indolyl-p-D-galactopyranoside (X-Gal) medium, and Luria
broth (16), and B. pertussis was grown on BG agar (26).
When appropriate, plasmid-bearing strains were grown with
100 ,ug of ampicillin per ml or 50 ,ug of chloramphenicol,
cephalexin, or kanamycin per ml. Bacterial cultures were
routinely grown at 37°C unless otherwise stated. Broth
cultures were aerated by shaking at 300 rpm in a New
Brunswick Environmental Incubator Shaker. Temperature
induction was carried out at 37°C, and isopropyl-p-D-thioga-
lactopyranoside (IPTG) induction was carried out by the
addition of 1.0 mM isopropyl-f-D-thiogalactopyranoside.
DNA manipulations. Restriction endonucleases, T4 DNA
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ligase, and polynucleotide kinase were used essentially by
the method of Maniatis et al. (16). Plasmids were isolated by
alkaline lysis (16). Transformation was carried out by the
method of Hanahan (7). Agarose gel electrophoresis was as
previously described (27). DNA sequencing was carried out
by the chain termination method of Sanger et al. (23).
Oligonucleotides were synthesized with an Applied Biosys-
tems model 380B DNA synthesizer used in accordance with
the manufacturer's instructions.
Reverse transcriptase mapping. RNA was isolated by
harvesting exponentially grown bacteria by centrifugation
(1.5 ml) and resuspending the pellet in 300 ,ul of a solution
containing 6.7 M guanidinium isothiocyanate, 1% (vol/vol)
,-mercaptoethanol, 2% (wt/vol) sodium-N-laurylsarcosine,
and 0.02 M sodium citrate (pH 7.0). The suspension was
incubated at 65°C for 10 min. Then, 300 ,ul of phenol
equilibrated with Tris-HCl (0.1 M, pH 8.0) was added, and
the suspension was incubated for 5 min at 65°C. A solution
(300 ,ul) of 0.1 M sodium acetate, 0.01 M Tris-HCl (pH 7.5),
and 1.0 mM EDTA which was followed by 400 ,ul of
chloroform-isoamylalcohol (24:1) was then added, mixed,
and incubated at 65°C for 10 min. After centrifugation at 4°C
for 10 min, the aqueous phase was reextracted once with
phenol-chloroform and twice with chloroform. After ethanol
precipitation, samples were treated with RNase-free DNase
I (Boehringer Mannheim) for 30 min at 20°C, reextracted
with phenol-chloroform, precipitated with ethanol, and re-
suspended in sterile water. The RNA concentration was
determined by measuring the A26, and the integrity of the
RNA was determined by the presence of discrete rRNA
bands after electrophoresis in 1.3% agarose gels.
For the primer extension analysis the 20-base primer
(3'-GACCGCCGGTAACGCAGGCG-5'; referred to as the
fim2RT primer) which is complementary to the noncoding
strand of the serotype 2 fimbrial subunit gene was synthe-
sized and labeled at the 5' end with T4 polynucleotide kinase
(Boehringer Mannheim) and [_y-32P]ATP (Amersham) as
previously described (16). Primer extension was carried out
essentially by the method of de Lorenzo et al. (4). Samples
were heated at 80°C for 10 min and electrophoresed as
described for DNA sequence reactions.
Transfer of broad-host-range plasmids to Bordetella spp. E.
coli strains containing both pRK600 and pDSK519 deriva-
tives were grown overnight in nutrient broth containing
antibiotics selective for both plasmids. A 1.0-ml sample of
each culture was pelleted by centrifugation at 3,000 x g for
15 min and resuspended in 1.0 ml of 0.9% NaCl. The
suspension was used to overlay 3-day-old plate cultures of
Bordetella spp., and the plates were incubated for 4 h at
37°C. The mating mixtures selecting for Bordetella spp.
recombinants with cephalexin and kanamycin were then
plated out.
Protein purification and analysis. Wild-type serotype 2
fimbriae from B. pertussis Tohama were dissociated from the
bacterial cell surface with 4 M urea at 60°C, partially purified
by the method of Mooi et al. (17), and further purified by
using CL-6B gel filtration chromatography following the
protocol of Irons et al. (8). Methionylated mature recombi-
nant protein was purified from inclusion bodies essentially
by the method of Nagai and Th0gersen (18), as modified by
Walker et al. (28). Protein samples were mixed 1:1 with
sample buffer (60 mM Tris-HCl [pH 6.8], 1% sodium dodecyl
sulfate [SDS], 1% 2-mercaptoethanol, 10% glycerol, 0.01%
bromophenol blue) and electrophoresed by the method of
Laemmli (12) with a 3.85% acrylamide stacking gel and a
10% acrylamide separating gel. Protein concentration was
determined by the method of Bradford (1).
Immunological techniques. Mouse antiserum was prepared
as previously described (28). Rabbit antiserum was prepared
by emulsifying 200 ,ug of protein at a ratio of 1:1 with Freund
incomplete adjuvant in a final volume of 1.0 ml. Groups of
two three-month-old chinchilla bastard rabbits were injected
subcutaneously and intramuscularly on day 1, day 14, and
day 28. After 35 days, the rabbits were sacrificed and the
blood was collected and allowed to clot for 3 h at room
temperature. Erythrocytes were pelleted at 9,000 x g, and
the serum was collected, pooled, and stored at -20°C until
use. Western immunoblotting was carried out essentially by
the method of Burnette (2). Antibodies that react with the
serotype 2 fimbrial subunit were raised in rabbits (see Fig.
3A) or mice (see Fig. 3B and C) (antisera were chosen on the
basis of least nonspecific reactivity). The detection system
used was Bio-Rad horseradish peroxidase-conjugated goat
anti-rabbit or goat anti-mouse immunoglobulin G with
4-chloro-1-naphthol as a substrate. Serotype-specific agglu-
tination and the preparation of serotype 2-specific antiserum
cross-adsorbed against B. pertussis H36, B. parapertussis
MIS180, and B. bronchiseptica 5376 were carried out as
previously described (20). For enzyme-linked immunosor-
bent assay (ELISA) and immunoelectron microscopy, cross-
adsorbed rabbit antibodies were purified by using a protein
A-Sepharose CL-4B column (Pharmacia) by applying the
recommended procedure and adjusting the protein concen-
tration to 400 jig of immunoglobulin G per ml. ELISA was
performed by adjusting protein concentrations to 10 ,ug/ml in
phosphate-buffered saline (pH 7.4; PBS) and allowing 100-,ul
triplicate samples and a PBS blank to adsorb to Nunc
Maxisorp Immunomodule 96-well plates overnight at 4°C.
Protein samples were removed, and wells were blocked with
200 RI1 of 0.3% gelatin in PBS for 2 h at 37°C. Plates were
washed three times with PBS, and a 50-,ul sample of 1:200
PBS-diluted serotype 2-specific rabbit antibodies was added
to each well. After 15 min at room temperature, the plates
were again washed and a 100-,ul sample of Bio-Rad horse-
radish peroxidase-conjugated goat anti-rabbit antibody di-
luted 1:1,000 in PBS was added to each well and incubated
for 1 h at room temperature. The plates were again washed
and then developed by the addition of 200 p.1 per well of
activated substrate solution (consisting of 10 ml of 0.1 M
citric acid, 10 ml of 0.2 M Na2HPO4, 20 ml of distilled H20,
40 pl of 30% H202, and 40 mg of o-phenyldiamine dihydro-
chloride). After an appropriate time, the reaction was
stopped by the addition of 50 ,ul of 0.25 M H2SO4 and the
A490 was determined with a Bio-Rad model 3550 microplate
reader. The standard deviation was calculated for each
triplicate sample.
Immunoelectron microscopy. Bacterial strains grown on
plates were gently suspended in 250 R1. of PBS, absorbed
onto freshly prepared collodium-covered nickel grids, and
then rinsed with distilled water. After being air-dried, the
grids were treated with a 1:100 dilution of the cross-adsorbed
serotype 2-specific antibody for 15 min at room temperature.
Unbound antibody was removed by a mild spray of PBS
from a plastic bottle. The bound antibodies were made
visible for electron microscopic examination by incubating
the grids on drops of protein A-gold complexes (10-nm gold
particle size, with a concentration (A520) = 0.01) for 10 min
at room temperature. The grids were subsequently rinsed
with a mild spray of PBS containing 0.01% Tween 20 and
then distilled water. After being air-dried the grids were
unidirectionally metal shadowed with platinum. Samples
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FIG. 1. Reverse transcriptase mapping of the transcriptional
start site of the wild-type serotype 2 fimbrial subunit gene of B.
pertussis Tohama (24) and the recombinant fimbrial subunit carried
by pMW10 (28). (A) Lanes G, A, T, and C, DNA sequence reactions
of pMW1O with the fim2RT primer; lanes 1 to 3, primer extension
analysis with the fim2RT primer of different RNA preparations
isolated from B. pertussis Tohama; lane 4, primer extension analysis
of strain CAG629 carrying pMW10 with the fim2RT primer. The
transcriptional start sites and the position of the first base in the
RNA message are relative to the adenosine (base +1) of the ATG
start codon and are indicated by arrows. For the wild-type fimbrial
subunit of B. pertussis Tohama, the start site is situated at base C
-146 (lower arrow, lanes 1 to 3) and at base A -173 for the
recombinant subunit found on pMW10 (upper arrow, lane 4). (B and
C) Diagrammatic representations of the upstream regions of the
wild-type gene (B) and recombinant fimbrial subunit (C). The
transcriptional start sites and their positions relative to the ATG
start codons are indicated by arrows. The ATG start codons and
were examined with a Zeiss electron microscope 10 B at an
acceleration voltage of 80 kV and at calibrated magnifica-
tions.
RESULTS
Reverse transcriptase mapping. To localize the native
promoter of the gene of the serotype 2 fimbrial subunit, the
transcriptional start site was defined by reverse transcriptase
mapping of purified B. pertussis Tohama RNA. The RNA
start site was situated 146 nucleotides upstream of the ATG
start codon (Fig. 1). The distance between the promoter and
the translational start site was taken into consideration in
subsequent experiments designed to clone the native pro-
moter and structural gene into the broad-host-range plasmid
pDSK519 (9) as described below. For the recombinant
serotype 2 fimbrial subunit expressed in E. coli, RNA was
isolated from E. coli CAG629(pMW10) (28) after induction
for 1 h at 42°C. Plasmid pMW10 contains a 0.8-kb fragment
carrying the gene of the serotype 2-specific fimbrial subunit
downstream of and in the same orientation as the lambda PL
and PR promoters of the expression vector pJLA503 (25).
This plasmid was designed to express an intact fimbrial
subunit protein with its original leader peptide. The subunit
gene had previously been modified to reduce the RNA
secondary structure between the atpE translational initiation
region (TIR) of the vector and the NH2-terminal coding
region so as to obtain efficient expression in E. coli (28). The
RNA start site was found to be located 173 nucleotides
upstream of the ATG start codon. This is in agreement with
the start site reported for the lambda PL promoter that is
incorporated upstream of the ATG start codon in the vector
pJLA503 (25). There was no evidence of another start site
further upstream correlating with the position of the lambda
PR promoter present in pJLA503 (Fig. 1). This is consistent
with the finding that less than 5% of transcripts originate
from the PR promoter in pJLA503 (16a).
Construction of expression plasmids. Broad-host-range
plasmids were constructed to transfer the B. pertussis sero-
type 2-specific fimbrial subunit gene, under the control of
native and E. coli expression signals, to B. parapertussis and
B. bronchiseptica. The modified subunit gene and atpE TIR
were subcloned from pMW10 into the broad-host-range
vector pDSK519 in the same orientation as the PLAC pro-
moter of the vector to produce pMW12. The modified gene,
atpE TIR, and PL and PR promoters were also subcloned into
pDSK519 in the opposite orientation to PLAC to produce
pMW14. Plasmid pMW11 was identical to pMW12, except
that the subunit gene encoding the methionylated mature
form of the fimbrial subunit gene (i.e., lacking leader pep-
tide) was cloned from pMW3 (28) into pDSK519. The
wild-type B. pertussis serotype 2 fimbrial subunit promoter
and structural gene was subcloned from plasmid pIL22 (15)
into pDSK519 to form pMW17 (in the same orientation as
PLAc) and pMW18 (in the opposite orientation) (Fig. 2).
Expression of recombinant fimbrial protein in E. coli.
Substantial amounts of the 25.0-kDa recombinant fimbrial
subunit were detected in E. coli CAG629 (lon protease-
deficient, heat shock protein-deficient) bacteria containing
consensus Shine-Dalgarno regions (SD) are underlined. The invert-
ed-repeat region of the wild-type gene is underlined with inverted
arrows. The DNA sequence of the upstream regions of the wild-type
and recombinant genes were taken from those reported for pIL22
(15) and pJLA503 (25), respectively.
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FIG. 2. Construction of broad-host-range plasmids to express the serotype 2 fimbrial subunit protein. Plasmid pIL22 (15) contains the
wild-type serotype 2 fimbrial subunit gene (st2, hatched box) and promoter (PWT, filled arrow) as a Sau3A fragment inserted into the BamHI
site of pBR328. Plasmid pMW1O contains the serotype 2 gene under the control of the lambda promoters PL and PR (filled arrows) (28). The
broad-host-range vector pDSK519 (9) contains the mob site of pRSF1OlO (mob, filled box), the lactose promoter (PLAC, filled arrow), and the
P-galactosidase a fragment (p-gal, open box). The lambda repressor (cl's857) and resistance genes for ampicillin (Bla), kanamycin (Kan) and
chloramphenicol (Cml) are also represented by open boxes. The direction of transcription of each gene is indicated by thin arrows. Plasmids
are not drawn to scale, and only relevant restriction sites are shown.
pMW12 and pMW14 after IPTG or temperature induction,
respectively, but not in the same host containing pDSK519,
which lacks the fimbrial gene insert; pMW17, which contains
the wild-type promoter and gene sequence (Fig. 3A); or
pMW18, which contains the same insert as pMW17 in the
opposite orientation. Methionylated mature fimbrial subunit
was also expressed from E. coli CAG629 containing pMWll
after IPTG induction. E. coli CAG629 expressing the fimbrial
subunit did not produce whole fimbriae as detected by
electron microscopic examination of the bacterial cell sur-
face (results not shown).
Expression of recombinant fimbrial protein in Bordetella
spp. Plasmids pDSK519, pMW11, pMW12, pMW14,
pMW17, and pMW18 were conjugally transferred to B. para-
pertussis M/S180, B. bronchiseptica 5376, and B. bronchi-
septica ATCC 10580. Western blot analysis showed that the
fimbrial subunit gene was expressed in B. parapertussis
M/S180 only when under the control of the wild-type B.
pertussis promoter and Shine-Dalgarno sequence. Similar
amounts of fimbrial subunit were produced independently of
the orientation of the subunit gene with respect to PLAC
(pMW17 and PMW18). No expression was detected from the
constructions designed to express the fimbrial subunit from
PLAC (pMW12) or lambda PL and PR (pMW14) promoters.
Recombinant B. parapertussis M/S180 containing pMW17 or
pMW18 produced higher levels of fimbrial subunit than B.
pertussis Tohama, presumably as a consequence of the
higher copy number of the subunit gene in these strains (Fig.
3B). In B. bronchiseptica 5376, the fimbrial subunit gene was
expressed at increasing levels by recombinants containing
pMW12, pMW18, and pMW17. The higher expression of
subunit in pMW17 over that in pMW18 may arise from both
PLAC and the native promoter working in tandem, which
would increase transcriptional levels of fimbrial subunit gene
in B. bronchiseptica pMW17. Expression of the subunit
protein from pMW12 suggests that PLAC and the atpE TIR
function in B. bronchiseptica but not in B. parapertussis.
However, no gene expression was detected in recombinants
containing pMW14, in which the fimbrial subunit gene is
under the control of the lambda promoters (Fig. 3C). No
fimbrial subunit expression was detected by Western blot
analysis in B. bronchiseptica ATCC 10580 containing
pMW12, pMW14, pMW17, or pMW18. This strain, in con-
trast to B. bronchiseptica 5376 and B. parapertussis M/S180,
did not produce native fimbriae (as determined by electron
microscopy) or filamentous hemagglutinin (analyzed by
BamHl
ligate
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FIG. 3. Western blot analysis with antiserum raised against the
recombinant fimbrial subunit purified from E. coli. (A) Lanes 1 to 4,
E. coli CAG629 containing pDSK519, pMW12, pMW14, and
pMW17, respectively; lane 5, B. pertussis Tohama (serotype 2); lane
6, prestained molecular mass markers (sizes given in kilodaltons).
(B) Lanes 1 to 5, B. parapertussis M/S180 containing pDSK519,
pMW12, pMW14, pMW17, and pMW18, respectively; lane 6, B.
pertussis Tohama (serotype 2). (C) Lanes 1 to 5, B. bronchiseptica
5376 containing pDSK519, pMW12, pMW14, pMW17, and pMW18,
respectively; lane 6, purified serotype 2 fimbriae. The fimbrial
subunit (fim 2) and molecular mass markers and their sizes (in
kilodaltons) are indicated by arrows. High-molecular-weight bands
represent proteins that cross-react with the rabbit (A) or mouse (B
and C) anti-serotype 2 subunit antiserum.
Western blotting). However, complementation of this strain
with the B. pertussis bvg locus resulted in the production of
both virulence-regulated phenotypes (results not shown). B.
bronchiseptica ATCC 10580 was therefore assumed to be a
bvg mutant. It was expected that pMW12 would still express
subunit protein in this strain since PLAC should function as a
constitutive promoter; the failure to do so may have arisen
M/S180 ATCC10580 5376
FIG. 4. Serotype 2-specific agglutination and ELISA with anti-
serotype 2 fimbrial antibodies cross-adsorbed against B. pertussis
H36, B. parapertussis M/S180, and B. bronchiseptica 5376. The
strains tested were B. pertussis Tohama, B. pertussis H36, B.
pertussis ATCC 9797, and derivatives of B. parapertussis M/S180,
B. bronchiseptica ATCC 10580, and B. bronchiseptica 5376 contain-
ing pDSK519, pMW12, pMW14, pMW17, or pMW18. Agglutination
ranged from slow (+) to medium (+ +) to fast (+ + +); those strains
that did not agglutinate after 5 min were not designated. ELISA
values (open bars) are expressed as A490 units per microgram of
protein.
from proteolytic degradation of the recombinant product
because of the lack of expression of appropriate fimbrial
accessory genes in this strain. Similarly, methionylated
mature fimbrial subunit was not detected in B. bronchisep-
tica 5376 containing pMWll (results not shown). The lack of
expression of such protein may have resulted from proteo-
lytic degradation of the fimbrial subunit in the cytoplasm of
the host.
Immunological characterization of recombinant fimbriae
expressed in BordeteUla spp. Serotype 2-specific agglutination
of the recombinant Bordetella spp. described above demon-
strated that the fimbrial accessory genes of both B. paraper-
tussis and B. bronchiseptica recognize and assemble B.
pertussis fimbrial subunit (Fig. 4). Furthermore, the rapidity
of agglutination paralleled the amount of fimbrial subunit
expressed, as seen in Western blots (Fig. 3). This result was
confirmed in ELISA experiments (Fig. 4). The highest levels
of expression were measured for B. bronchiseptica 5376
(pMW17) and B. parapertussis MIS180(pMW17)(pMW18),
which were followed by B. bronchiseptica 5376(pMW18) and
B. pertussis Tohama and then finally by B. bronchiseptica
5376(pMW12). The values obtained for strains containing
pMW12 were slightly higher than in those strains containing
the vector alone (pDSK519) or the other recombinant plas-
mids, as can be most clearly seen for B. bronchiseptica
ATCC 10580. This may be due to a nonspecific response.
The reason for this nonspecific reaction was not investi-
gated.
Immunoelectron microscopic examination of recombinant
Bordetella spp. confirmed the fimbrial nature of the product.
Those strains that did not express the serotype 2 fimbrial
subunit, as represented by both B. parapertussis MIS180 and
B. bronchiseptica 5376 harboring pDSK519 (Fig. SB and D)
were not labeled by protein A-gold complexes after incuba-
tion with serotype 2-specific antibody, even though wild-
type fimbriae were present. On the other hand, when sero-
A
fim 2
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FIG. 5. Immunoelectron microscopic localization of serotype 2 fimbrial protein by using the protein A-gold procedure. Cells were
adsorbed to collodium films, air-dried, and incubated with serotype 2 fimbrial antiserum that had been cross-adsorbed with B. pertussis H36,
B. parapertussis M/S180, and B. bronchiseptica 5376 bacteria. The bound antibodies were visualized by incubation with protein A-gold
complexes (10 nm). Shown are B. pertussis Tohama (A); B. parapertussis M/S180 containing pDSK519 (B) and pMW17 (C); and B.
bronchiseptica 5376 containing pDSK519 (D), pMW12 (E), and pMW17 (F). G, Gold particle; F, fimbriae. Bars, 0.25 p.m.
type 2-specific fimbriae were produced, as represented by B.
pertussis Tohama, B. parapertussis M/S180(pMW17), and B.
bronchiseptica 5376 containing pMW12 or pMW17, the
fimbriae were specifically labeled (Fig. 5A, C, E, and F). The
fate of the original fimbrial subunit in these recombinant
strains is unknown since most of the fimbriae produced in
strains expressing the serotype 2 subunit are antibody la-
beled. In B. bronchiseptica 5376(pMW12), in which serotype
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RECOMBINANT B. PERTUSSIS SEROTYPE 2 FIMBRIAE
2 subunit expression is least, the intensity of fimbrial immu-
nolabeling was decreased compared with B. pertussis To-
hama and B. bronchiseptica 5376(pMW17) fimbriae. This
suggests that the fimbriae are of a mixed nature, containing
both wild-type and recombinant fimbrial subunits. Fimbriae
were not detected on every bacterium for all the strains
tested which were taken from BG plates (Fig. 5D and E). It
was found that vigorous resuspension of cells resulted in loss
through shearing of almost all fimbriae and that gentle cell
suspension was a critical step in fimbrial detection. How-
ever, fimbrial phase variation may also play a role in this
process (30).
DISCUSSION
It has been demonstrated that the serotype 2 fimbrial
subunit protein is immunologically distinct from whole fim-
briae (14). In an earlier communication, we reported expres-
sion of the B. pertussis serotype 2 fimbrial subunit in E. coli.
After purification and renaturation, the subunit assembled to
form fimbriallike structures. However, although the recom-
binant subunit polymers and wild-type fimbriae were com-
posed of the same protein subunit, they exhibit only limited
cross-reactivity (28). In this report we demonstrate that
recombinant serotype 2 fimbrial subunit is produced in
Bordetella spp. expressing fimbrial accessory genes as fim-
briae that are indistinguishable from native fimbriae. As was
previously shown for the pertussis toxin promoter (13), the
serotype 2 fimbrial subunit promoter was found to function
in both B. parapertussis and B. bronchiseptica. Although the
regions upstream of both the pertussis toxin operon and the
serotype 2 fimbrial subunit gene show some degree of
homology (30), the distances between the start sites of
transcription and translation are very different, namely, 25
nucleotides in the case of the pertussis toxin Si subunit (19a)
and 146 nucleotides in the case of the serotype 2 fimbrial
subunit gene. Expression of fimbriae in B. pertussis is
controlled by the bvg virulence regulatory locus and is
subject to fimbrial phase variation. Recently, Willems et al.
(30) reported that fimbrial phase variation may be due to
insertion-deletion events within a C-rich region located some
57 nucleotides upstream of the ATG start site of the serotype
2 subunit gene. However, further investigation is required to
determine whether or not other factors, including the in-
verted repeat region that overlaps the wild-type transcrip-
tional start site (Fig. 1B), are involved in the control of
fimbrial expression.
In contrast to B. parapertussis, in which only the native B.
pertussis promoter was functional, the heterologous expres-
sion signals PLAC and the atpE TIR functioned in B. bron-
chiseptica 5376 to express the fimbrial subunit. Although this
construction was expected to function constitutively, the
fimbrial subunit was not detected by Western blot analysis in
nonfimbriated B. bronchiseptica ATCC 10580. The lack of
fimbrial accessory gene expression as a result of the bvg
mutant genotype of this strain may result in proteolytic
degradation of the fimbrial subunit. Similarly, another con-
struction designed to express the methionylated mature form
of the fimbrial subunit did not produce detectable levels of
subunit protein in B. bronchiseptica 5376. These experi-
ments highlight the importance of fimbrial accessory genes
and correct processing and transport of the fimbrial subunit
to the periplasm: loss of either function results in a total
absence of product accumulation. We are currently trying to
isolate the B. pertussis fimbrial accessory genes, with the
expectation that constitutive expression of such genes may
facilitate the expression of B. pertussis fimbriae in B. bron-
chiseptica and E. coli strains.
For the preparation of a recombinant acellular whooping
cough vaccine, purified antigens that are immunologically
similar to the wild-type form must be produced. It has been
shown that both recombinant pertussis toxin and serotype 2
fimbrial subunit are antigenically distinct when prepared
from E. coli (3, 28) but that recombinant pertussis toxin
subunits produced in B. parapertussis and B. bronchiseptica
assemble as native holotoxin (13). As shown here, recombi-
nant serotype 2 fimbrial subunit is also produced as whole
fimbriae in Bordetella spp. expressing fimbrial accessory
genes. Such bacteria offer several advantages for antigen
production over B. pertussis with regard to growth rates and
requirements (13). Furthermore, the fimbrial subunit was
expressed in B. bronchiseptica under the control of PLAC
and the atpE TIR. The constitutive expression of vaccine
components in B. bronchiseptica may offer considerable
advantages in terms of product yields.
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